Biodesix, Inc..
BDSX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Biodesix, Inc. is a data-driven diagnostic solutions company with a focus on lung disease. The company develops and commercializes diagnostic tests that provide clinically actionable information to help physicians make better treatment decisions for patients with lung cancer and other lung diseases....Show More
Better Health for All
40
Biodesix demonstrates a commitment to better health for all through its lung cancer diagnostic tests. The Nodify Lung tests aim to improve lung cancer detection and reduce unnecessary biopsies, with studies showing a potential 74% relative reduction of invasive procedures for benign nodules.
1
The GeneStrat NGS test expedites access to targeted therapies, with Medicare coverage enhancing price accessibility.
2
A partnership with APAPP aims to improve lung cancer diagnostics education in underserved areas, reaching 30-40% of lung cancer patients in those regions.
3
The VeriStrat test predicts overall survival in NSCLC patients, with 'VeriStrat Poor' patients experiencing a more than tripled two-year survival rate with combined immunotherapy and chemotherapy compared to immunotherapy alone.
4
The company launched a new blood draw method using the Tasso+ device to improve access to Nodify Lung testing.
5
However, there is a lack of information on long-term outcomes, cost-effectiveness, and specific details on health equity programs.
6
,
7
,
8
Fair Money & Economic Opportunity
0
Biodesix, Inc. is a diagnostic solutions company focused on lung disease, developing and commercializing diagnostic tests.
1
The company does not offer lending, insurance, or deposit services to consumers, nor does it engage in activities that lend, insure, move, or store money as defined by the 'Fair Money & Economic Opportunity' value. While Biodesix offers financial support programs (Biodesix Assist Financial Support Program, Biodesix Access Program) to help patients with the cost of medical tests,
2
these initiatives are related to healthcare access rather than financial inclusion or economic opportunity in the context of financial services. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcome, profit reinvestment, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its core business model.
Fair Pay & Worker Respect
0
No evidence available to assess Biodesix, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No data relevant to fair trade and ethical sourcing practices, including quantitative metrics, regulatory actions, certifications, or comparisons, was found in the provided articles for Biodesix, Inc.
1
Honest & Fair Business
0
No specific, concrete data points were provided in the articles for any of the KPIs related to Honest & Fair Business, such as regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy index, complaint resolution time, board conflict of interest, anti-corruption policies, or third-party verification.
1
Kind to Animals
0
No specific, concrete evidence related to Biodesix, Inc.'s performance on any 'Kind to Animals' KPIs was found in the provided articles. The articles did not contain data on cruelty-free certifications, alternative testing usage, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare, cage-free sourcing, animal testing policy or volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement regarding animal welfare.
1
No War, No Weapons
0
The provided articles state that Biodesix, Inc. has secured a U.S. Federal Supply Schedule contract for its lung cancer diagnostic portfolio, which includes the Veterans Health Administration and the Military Health System.
1
While this indicates a contractual relationship with a military entity, the articles do not provide any specific quantitative data regarding the percentage of company revenue derived from this or any other defense-related contracts. Furthermore, the company's core business is described as diagnostic solutions for lung disease, and the contract is specifically for lung cancer diagnostic tests, which are civilian healthcare products.
2
There is no evidence of involvement in arms manufacturing, dual-use technology with military applications, sales to embargoed regimes, or any other activities directly related to war or weapons as defined by the negative scoring tiers. Without concrete, quantifiable data points for any of the KPIs, no scores can be assigned.
Planet-Friendly Business
-40
The company has a stated commitment to achieve net-zero by 2040 through the Amazon Climate Pledge.
1
However, no specific emissions data or reduction targets are publicly available, indicating that interim targets are undefined.
2
Respect for Cultures & Communities
0
The company's operations, focused on diagnostic solutions for lung disease, do not inherently involve activities that typically lead to cultural appropriation incidents, require cultural impact assessments, FPIC processes, community governance inclusion, cultural preservation investments, cultural site protection, or social licenses to operate.
1
No cultural appropriation incidents or cultural incidents requiring a response have been reported in the provided articles.
2
Therefore, these KPIs are scored as '0' due to their non-applicability to the business model or lack of reported incidents.
Safe & Smart Tech
0
No evidence available to assess Biodesix, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-50
The company has implemented the Biodesix Collection Device (BCD), which reduces the need for processing equipment like centrifuges in clinics, representing a waste reduction initiative.
1
The BCD also reduces the costs and environmental impact associated with shipping blood tubes, indicating an improvement in material efficiency.
2
The company states a commitment to reducing waste generation and minimizing the use of environmentally damaging substances, and expects employees to comply with environmental laws.
3